Matched sibling or alternative donor HCT, orHiDAC 1.5‐3 g/m2 every 12 h on days 1, 3, 5 or 1, 2, 3 × 3‐4 cycles, orHiDAC 1.5‐3 g/m2 every 12 h on days 1, 3, 5 or 1, 2, 3 with oral midostaurin 50 mg every 12 h on days 8‐21 (FLT3‐mutated AML), orDual‐drug liposomal encapsulation cytarabine 65 mg/m2 and daunorubicin 29 mg/m2 on days 1 and 3 (cytotoxic therapy‐related AML or patients with antecedent MDS/CMML or cytogenetic changes consistent with MDS). This evidence concerns the gene FLT3 and chronic myelomonocytic leukemia.